Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 0 · FY2023 5,024 · FY2024 7,803 — 3-yr total 12,827
Aversi-Pharma is Georgia's leading pharmacy chain, founded 1994 as a family-run pharmaceutical distributor. Operates 332 stores and the largest pharmaceutical factory in Georgia, employs 10,000+ people, and since 2007 runs Aversi Clinic — a multi-profile medical-diagnostic chain across the Caucasus.
Group parent — controls 4 companies · ownership
| Line item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Net Cash from Operating Activities | 21,585 | 38,943 | 37,624 | 49,576 | 79,921 | 76,990 | 70,618 | 84,310 | +21.5% |
| Net Cash used in Investing Activities | 0 | 36,744 | 29,433 | 23,206 | 57,649 | 30,778 | 53,564 | 72,350 | +12.0% |
| Free Cash Flow (OCF − Capex proxy) | 21,585 | 2,199 | 8,191 | 26,370 | 22,272 | 46,212 | 17,054 | 11,960 | -8.1% |
| Net Cash from Financing Activities | 0 | 2,875 | 22,751 | 22,964 | 27,419 | 22,997 | 9,841 | 18,973 | nmf |
| Net Change in Cash (before FX) | 21,585 | 5,074 | 14,560 | 3,406 | 5,147 | 23,215 | 7,213 | 7,013 | nmf |
| Effect of FX on Cash | 0 | 114 | 71 | 133 | 96 | 623 | 167 | 286 | nmf |
| Net Change in Cash (incl. FX) | 21,585 | 5,188 | 14,489 | 3,273 | 5,243 | 22,592 | 7,046 | 7,299 | nmf |
| Cash at Beginning of Year | 0 | 21,056 | 26,244 | 11,755 | 15,028 | 9,785 | 32,377 | 39,423 | +11.0% |
| Cash at End of Year | 0 | 26,244 | 11,755 | 15,028 | 9,785 | 32,377 | 39,423 | 32,124 | +3.4% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →